Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis, Inc. ( CRIS ) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma July 22, 2026 8:30 AM EDT

Company Participants Diantha Duvall - CFO and Principal Financial & Accounting Officer James Dentzer - President, CEO, Secretary, Treasurer & Director Ahmed Hamdy - Chief Medical Officer

Conference Call Participants Srikripa Devarakonda - Truist Securities, Inc., Research Division Yale Jen - Laidlaw & Company ( UK ) Ltd., Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Boris Peaker - JonesTrading Institutional Services, LLC, Research Division

Presentation Operator Good morning, and welcome to Curis' Emavusertib Update Call. [Operator Instructions] Please note that this event is being recorded. And I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Diantha, please go ahead.

Diantha Duvall CFO and Principal Financial & Accounting Officer Thank you, and welcome to Curis' Emavusertib Update Call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find the Curis announces positive emavusertib update press release. I would also like to remind everyone that during our call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; Dr. Ahmed Hamdy, Chief Medical Officer; and Dr. Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim. James Dentzer President, CEO, Secretary, Treasurer & Director Thank you, Diantha. Good morning, everyone, and welcome to Curis' Emavusertib Update Call. We're excited to report updated data from the TakeAim lymphoma study in